Overall Fundamental outlook

* AJANTPHARM makes the list of companies with the best fundamentals at present.

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for AJANTPHARM
Revenue projections for AJANTPHARM

AJANTPHARM's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 0.000000
forwardPE 29.571426
debtToEquity 5.698000
earningsGrowth 0.179000
revenueGrowth 0.200000
grossMargins 0.762670
operatingMargins 0.246380
trailingEps 81.130000
forwardEps 99.400000

Ajanta Pharma Limited's Forward PE is well-positioned, indicating the stock price is favorable compared to its earnings. This suggests the stock is not overpriced and offers room for growth, making it an attractive option for investors looking for future value appreciation.
AJANTPHARM's positive earnings and revenue growth indicate that the company is on track to expand its business. This growth suggests a strong financial outlook, with increasing profits and sales positioning AJANTPHARM for continued success in the market.
AJANTPHARM's positive gross and operating margins suggest the company is performing profitably. These margins reflect efficient cost management and strong revenue generation, signaling healthy financial performance and operational effectiveness.
Ajanta Pharma Limited's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting Ajanta Pharma Limited to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for AJANTPHARM
Price projections for AJANTPHARM

AJANTPHARM's price projections have been revised higher over time, reflecting increased confidence in the company's future potential. This steady upward trend suggests analysts expect AJANTPHARM to continue its positive trajectory.

Insider Transactions:

Insider Transactions for AJANTPHARM
Insider Transactions for AJANTPHARM


There were 7 transactions selling AJANTPHARM stock, with prevailing market price of 2692.714285714286.No sell transactions were completed during the period under review.More buys than sells have been occurring around the current price levels of AJANTPHARM, potentially signaling investor optimism. This buying trend might be interpreted as a sign of a favorable outlook for the stock's future performance.

Recommendation changes over time:

Recommendations trend for AJANTPHARM
Recommendations trend for AJANTPHARM


Ajanta Pharma Limited has received a favorable buy bias from analysts recently, positioning it as a solid investment opportunity. This sentiment may attract more investors, who view Ajanta Pharma Limited as a stable option to park their money and potentially benefit from the company's continued growth and profitability.